RETRO CRVO: Retrospective Data Analysis of Patients Treated for Macular Edema Due to Central Retinal Vein Occlusion
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- Bayer
- 入组人数
- 126
- 主要终点
- Treatment duration
研究概览
简要总结
The objective of this retrospective chart review is to evaluate drug utilization, usage patterns and indication of effectiveness Eylea in the routine clinical (real-life) management of patients who suffer from ME (Macular Edema), secondary to CRVO (Central Retinal Vein Occlusion), and who started treatment with Eylea for this indication.
研究设计
- 研究类型
- Observational
- 观察模型
- Other
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female adult patients who suffer from visual impairment due to ME secondary to CRVO
- •Anti-VEGF treatment-naive patients who started reimbursed Eylea treatment between the 1st of June 2014 and the 28th of February 2015
排除标准
- •Patients diagnosed with neovascular glaucoma secondary to CRVO will be excluded.
研究组 & 干预措施
Group 1
The source population of this study is patients who suffer from visual impairment due to ME secondary to CRVO. In order to ensure the representativeness of the study population, the number of Belgian patients which started Eylea treatment during the brief period between the 1st of June 2014 and the 28th of February 2015 were taken into account. However, data of patients diagnosed with neovascular glaucoma secondary to CRVO will be excluded.
干预措施: Aflibercept (Eylea, BAY86-5321) (Drug)
结局指标
主要结局
Treatment duration
时间窗: At 12 months of treatment with Eylea
Number of eyes treated (mono-and biocular)
时间窗: At 12 months of treatment with Eylea
Change in visual acuity (BCVA score)
时间窗: At 12 months of treatment with Eylea
Number of Eylea injections per treated eye
时间窗: At 12 months of treatment with Eylea
次要结局
- Estimation of percentage (%) of eyes which need additional treatment after 2 years at the discretion of the treating physician.(At 12 months of treatment with Eylea)
- Number of patients who discontinued their treatment with Eylea prematurely(At 12 months of treatment with Eylea)
- Sufficiency of reimbursed number of Eylea injections (max. 9 injections/eye in year 1) for treatment of all patients during the first year of treatment.(At 12 months of treatment with Eylea)